2023 Full Year Guidance

RECENT ANNOUNCEMENTS | ↑ ↑ ↑ CENTENE CONTRACT 5 year pharmacy benefit services contract starting 1/1/24 driving value and lower costs for ~20M Centene members Implementation headwind in 2023, neutral to slightly positive in 2024, run-rate margin in 2025+ Financially accretive over the contract period 7/7 BIOSIMILARS Driving lower costs by adding Humira biosimilars to National Preferred Formulary Humira will remain as co-preferred providing choice and flexibility Other biosimilars will be evaluated as they come to market VillageMD AND SUMMIT Up to $2.7B equity investment for ~14% stake in combined company Attractive 5.5% annual dividend on $2.2B of $2.7B investment Innovative partnership accelerating our value based care strategy Confidential, unpublished property of Cigna. 2023 Cigna

View entire presentation